AU Patent

AU2020202756B2 — Treating infections with Ceftolozane/Tazobactam in subjects having impaired renal function

Assigned to Merck Sharp and Dohme LLC · Expires 2021-12-23 · 4y expired

What this patent protects

Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra abdominal infection or a complicated urinary tract infection.

USPTO Abstract

Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra abdominal infection or a complicated urinary tract infection.

Drugs covered by this patent

Patent Metadata

Patent number: AU2020202756B2
Jurisdiction: AU
Classification: —
Expires: 2021-12-23
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.